Study: TAVR, surgical AVR results similar at 2 years in intermediate risk patients

Transcatheter and surgical aortic valve procedures were shown to have similar outcomes at 2 years in severe aortic stenosis patients deemed to be at intermediate surgical risk, according to a recently published study. Data came from a 2-year follow up with patients in the Partner 2 trial, which aimed to explore the difference between the 2 procedures in intermediate risk patients. A total of 2,032 patients were examined in the trial, which was randomly divided into 2 cohorts, with the 1st receiving Edwards Lifesciences‘(NYSE:EW) Sapien XT and the 2nd receiving a surgical AVR procedure. At 2 years, both disease-specific and generic health statuses showed significant improvements in both arms of the study. TAVR patients showed better health statuses than those treated with AVR at 1 month, but only in patients treated via transferal access, but researchers found no significant differences between TAVR and surgical AVR patients in any health measures at 1 or 2 years. “Among intermediate-risk patients with severe AS, health status improved significantly with both TAVR and SAVR through 2 years of follow up. Early health status improvement was greater with TAVR, but only among patients treated via transfemoral access. Longer term follow-up is needed to assess the durability of quality-of-life improvement with TAVR vs SAVR in this population,” study authors wrote in their conclusions. The post Study: TAVR, surgical AVR results similar at 2 years in intermediate ris...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves Edwards Lifesciences Source Type: news